ABSENT CD33 IN AML PATIENTS: FROM DIAGNOSIS TO FOLLOW-UPS

ABSENT CD33 IN AML PATIENTS: FROM DIAGNOSIS TO FOLLOW-UPS

Background: Despite recent advances and development of new therapeutic targets and personalized medicine, acute myeloid leukemia (AML) treatment remains defiant. Identification of residual leukemic cells (measurable residual disease -MRD) by Multiparametric Flow Cytometry has been a fast and effecti...

Full description

Bibliographic Details
Main Authors:	Leticia O. Marani, Amanda Costa, Fernanda B. Silva, Maria Izabel A. Madeira, Priscila S. Scheucher, Josiane L.S. Schiavinato, Ana Silvia G. Lima, Katia B.B. Pagnano, Bruno K. Duarte, Sylvie Freeman, Eduardo M. Rego, Fabiola Traina, Lorena L. Figueiredo-Pontes
Format:	Article
Language:	English
Published:	Elsevier 2023-04-01
Series:	Hematology, Transfusion and Cell Therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2531137923000482

Similar Items

ABSENT CD33 IN AML PATIENT MIMICS MRD POSITIVE: A SINGLE CASE REPORT
by: LO Marani, et al.
Published: (2021-10-01)

PB1814: RARE PHENOTYPE WITH CD33 ABSENT IN ACUTE MYELOID LEUKEMIA MIMICKING MRD POSITIVITY: A CASE REPORT
by: L. O Marani, et al.
Published: (2022-06-01)

DOENÇA RESIDUAL MENSURÁVEL POR CITOMETRIA DE FLUXO MULTIPARAMÉTRICA É VIÁVEL E DETERMINA RISCO PROGNÓSTICO DINÂMICO EM PACIENTES DE UMA COORTE BRASILEIRA DE LEUCEMIA MIELOIDE AGUDA
by: LO Marani, et al.
Published: (2023-10-01)

RECLASSIFICAÇÃO DA LEUCEMIA MIELOIDE AGUDA DE ACORDO COM A CÉLULA DE ORIGEM FENOTIPICAMENTE DEFINIDA
by: RCB Macedo, et al.
Published: (2023-10-01)

P396: DYSREGULATED DNAM-1 AND KIR2DL1 EXPRESSION IN NATURAL KILLER CELLS CORRELATES WITH POOR OUTCOME IN ACUTE MYELOID LEUKEMIA
by: A. F O Costa, et al.
Published: (2022-06-01)

FREQUÊNCIA E ATIVAÇÃO DE CÉLULAS CITOTÓXICAS ANTITUMORAIS SÃO BIOMARCADORES DE RESPOSTA E REMISSÃO LIVRE DE TRATAMENTO NA LEUCEMIA MIELOIDE CRÔNICA
by: LS Binelli, et al.
Published: (2023-10-01)

UNRAVELLING THE HIGH INCIDENCE OF ACUTE MYELOID LEUKEMIA WITH MONOCYTIC BLAST DIFFERENTIATION IN A BRAZILIAN MULTICENTER STUDY
by: LO Marani, et al.
Published: (2021-10-01)

AVALIAÇÃO DE VIABILIDADE DE DETECÇÃO DE DRM EM LLA-B POR CITOMETRIA DE FLUXO MULTIPARAMÉTRICA INDEPENDENTE DE CD19
by: R Pacca, et al.
Published: (2023-10-01)

Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
by: Kersemans, V, et al.
Published: (2008)

AML Risk Adjusted Performance Indicators: Assumptions & Methodology
by: Ivano Traina, et al.
Published: (2022-04-01)

MATURAÇÃO FUNCIONAL E ATIVAÇÃO DE CÉLULAS NATURAL KILLER DISTINGUEM MIELOFIBROSE PRÉ-FIBRÓTICA E FIBRÓTICA
by: M Medeiros, et al.
Published: (2023-10-01)

Absent anterior cruciate ligament
by: S Vanden Bossche, et al.
Published: (2015-09-01)

HIGH FREQUENCY OF LEUKEMIC STEM CELLS IS ASSOCIATED WITH ADVERSE PROGNOSIS IN A BRAZILIAN COHORT OF ACUTE MYELOID LEUKEMIA WITH NORMAL KARYOTYPE
by: G.L. Jacovelli, et al.
Published: (2020-11-01)

Democratic theory and the present/absent international
by: R.B.J. Walker
Published: (2010-02-01)

The Guardian is Absent
by: Pola Cebulak, et al.

Image of the Absent
by: Ayellet Ben Ner
Published: (2015-10-01)

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials
by: Gale, R, et al.
Published: (2018)

Absent Histories and Absent Images: Photographs, Museums and the Colonial Past
by: Elizabeth Edwards, et al.
Published: (2013-03-01)

Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7
by: Hiroyoshi Kunimoto, et al.
Published: (2020-10-01)

Leucemia Mielóide Crônica: causas de falha do tratamento com mesilato de imatinibe Chronic Myeloid Leukemia: causes of treatment failure with imatinib
by: Katia B. B. Pagnano
Published: (2008-04-01)

Avaliação das proteínas reguladoras do ciclo celular e apoptose nos Linfomas não-Hodgkin agressivos e influência na resposta ao tratamento Evaluation of cell cycle and apoptosis-regulating proteins in aggressive non-Hodgkin's lymphomas and influence in response to treatment
by: Katia B. B. Pagnano
Published: (2004-01-01)

Interpeler l’absent.
by: Marie-Laure Florea

Le peuple absent
by: Nejma Kermele
Published: (2017-12-01)

The 'Voice' of Absent Designers
by: Annika Lantz-Andersson, et al.
Published: (2011-01-01)

Evaluation The Role of CD33+ CD11b+ myeloid-derived Suppressor Cells in Patients With AML
by: Hala Hamad, et al.
Published: (2022-07-01)

IMPROVING MORTALITY IN AML IN LOW-TO-MEDIUM-INCOME COUNTRIES (LMIC): THE IMPACT OF SELECTIVE DIGESTIVE TRACT DECONTAMINATION WITH GENTAMYCIN, VORICONAZOLE PROPHYLAXIS AND SINGLE-BED ROOMS
by: B.K.L. Duarte, et al.
Published: (2020-11-01)

The not-so-absent-minded driver
by: Board, O
Published: (2003)

The Not-So-Absent-Minded Driver.
by: Board, O
Published: (2003)

Retour de l’absent
by: Claire Demesmay, et al.
Published: (2018-11-01)

THE ABSENT GEOPOLITICS OF PURE CAPITALISM
by: Radhika Desai
Published: (2010-09-01)

Listening by ‘Staying With’ the Absent Child
by: Alex Orrmalm, et al.
Published: (2022-10-01)

Kant and the Modernity of the Absent Public
by: Jarzombek, Mark
Published: (2019)

Poland syndrome with absent ribs
by: Rupam Kumar Ta, et al.
Published: (2014-01-01)

On finding minimal absent words
by: Garcia Sara P, et al.
Published: (2009-05-01)

Endlessly Signifying What Is Absent
by: Jean Frémon
Published: (1987-08-01)

The “absent” left atrial appendage…
by: Faraz Kureshi, MD, MSc, et al.
Published: (2017-10-01)

Absent friends in shared landscapes
by: Lorna Edwards
Published: (2020-10-01)

S104: DIFFERENTIAL TARGET PROFILES AND EFFICACY OF ADCLEC.SYN1 AND CD33-CARS IN HUMANIZED AML MODELS
by: Sascha Haubner, et al.
Published: (2023-08-01)

S133: OFF-THE-SHELF CD33 CAR-NK CELL THERAPY FOR RELAPSE/REFRACTORY AML: FIRST-IN-HUMAN, PHASE I TRIAL
by: R. Huang, et al.
Published: (2022-06-01)

Evidence that urocortin is absent from neurons of the Edinger-Westphal nucleus in pigeons
by: Cavani J.A., et al.
Published: (2003-01-01)